Table of Contents
<< Previous Issue | Apr 2022 (Vol: 2022, Issue: 4) | Next Issue >> |
- Section: Mergers & Acquisitions
-
Pfizer Bolsters RSV Pipeline with US$525 M ReViral Acquisition
-
GlaxoSmithKline Gets Momelotinib with US$1.9 B Sierra Oncology Buyout
-
Regeneron Bolsters I-O Portfolio with US$250 M Checkmate Acquisition
-
Caladrius and Cend Merge to Become Lisata Therapeutics
- Section: Research & Development
-
Takeda Signs US$400 M+ Gene Therapy Pact with Evozyne